Lupin Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for OralSuspension.".
Lupin Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for OralSuspension.".